These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24716688)

  • 1. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Laske C
    N Engl J Med; 2014 Apr; 370(15):1459. PubMed ID: 24716688
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    de la Torre JC
    N Engl J Med; 2014 Apr; 370(15):1459-60. PubMed ID: 24716689
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Salloway S; Sperling R; Brashear HR
    N Engl J Med; 2014 Apr; 370(15):1460. PubMed ID: 24724181
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Doody RS; Farlow M; Aisen PS;
    N Engl J Med; 2014 Apr; 370(15):1460. PubMed ID: 24716687
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immunotherapy for Alzheimer's disease].
    Falkentoft AC; Hasselbalch SG
    Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
    Imbimbo BP; Ottonello S; Frisardi V; Solfrizzi V; Greco A; Seripa D; Pilotto A; Panza F
    Expert Rev Clin Immunol; 2012 Feb; 8(2):135-49. PubMed ID: 22288451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].
    Peters O
    Dtsch Med Wochenschr; 2014 Mar; 139(10):468. PubMed ID: 24570189
    [No Abstract]   [Full Text] [Related]  

  • 8. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
    Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
    Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
    N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solanezumab and the amyloid hypothesis for Alzheimer's disease.
    Le Couteur DG; Hunter S; Brayne C
    BMJ; 2016 Dec; 355():i6771. PubMed ID: 28034844
    [No Abstract]   [Full Text] [Related]  

  • 13. Sixty seconds on . . . solanezumab.
    Hawkes N
    BMJ; 2016 Nov; 355():i6389. PubMed ID: 27899350
    [No Abstract]   [Full Text] [Related]  

  • 14. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
    Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
    Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiamyloid therapy for Alzheimer's disease--are we on the right road?
    Karran E; Hardy J
    N Engl J Med; 2014 Jan; 370(4):377-8. PubMed ID: 24450897
    [No Abstract]   [Full Text] [Related]  

  • 18. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?
    Tayeb HO; Murray ED; Price BH; Tarazi FI
    Expert Opin Biol Ther; 2013 Jul; 13(7):1075-84. PubMed ID: 23574434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.